Gabapentin Toxicity and Role of Dialysis; Case Series and Literature Review
Main Article Content
Keywords
dialysis, gabapentin, myoclonus
Abstract
Gabapentin is frequently used as an analgesic in patients with chronic kidney disease (CKD). It is excreted exclusively through kidney, and therefore impairment in kidney function could lead to gabapentin accumulation and hence toxicity. We present our experience of 3 cases with Gabapentin toxicity who were managed according to the severity of symptoms. Case 1: A 32-year-old male was found lying unconscious after consuming around 12,000 mg of gabapentin and had respiratory depression, rhabdomyolysis, and acute kidney injury (AKI). Patient was managed with supportive care and hemodialysis (HD). Case 2: A 64-year-old male CKD Stage 5 (5D) patient with diabetic neuropathy was started on gabapentin 300 mg daily by his primary care physician 1 week back. Patient started to feel sleepy and developed altered sensorium and myoclonus. Discontinuation of gabapentin and a session of HD led to dramatic improvement in patient’s status. Case 3: A 70-year-old female diabetic patient with CKD Stage 3 and had diabetic neuropathy. Her neuropathic symptoms had improved with gabapentin 300 mg twice daily, but lately patient was feeling sleepy during the day and was confused. Discontinuation of the drug led to improvement in symptoms. Gabapentin is a relatively safe medication, but in certain clinical scenarios, particularly in impaired renal functions, can lead to severe complications. Moreover, it per se can rarely lead to rhabdomyolysis and AKI. Clinical suspicion and timely decontamination are needed, and sometimes dialytic therapy may be needed.
References
2. Dogukan A, Aygen B, Berilgen MS, Dag S, Bektas S, Gunal AI. Gabapentin-induced coma in a patient with renal failure. Hemodial Int. 2006;10:168–9. 10.1111/j.1542-4758.2006.00089.x
3. Miller A, Price G. Gabapentin toxicity in renal failure: The importance of dose adjustment. Pain Med. 2009;10:190–2. 10.1111/j.1526-4637.2008.00492.x
4. Hung T-Y, Seow V-K, Chong C-F, Wang T-L, Chen C-C. Gabapentin toxicity: An important cause of altered consciousness in patients with uraemia. Emerg Med J. 2008;25:178–9. 10.1136/emj.2007.053470
5. Jones H, Aguila E, Farber HW. Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis. Ann Intern Med. 2002;137(1):74. 10.7326/0003-4819-137-1-200207020-00029
6. Qiu X, Tackett E, Khitan Z. A case of gabapentin overdose induced rhabdomyolysis requiring renal replacement therapy. Clin Case Rep. 2019;7:1596–9. 10.1002/ccr3.2302
7. Kaufman KR, Parikh A, Chan L, Bridgeman M, Shah M. Myoclonus in renal failure: Two cases of gabapentin toxicity. Epilepsy Behav Case Rep. 2014;2:8–10. 10.1016/j.ebcr.2013.12.002
8. Lau T, Leung S, Lau W. Gabapentin for uremic pruritus in hemodialysis patients: A qualitative systematic review. Can J Kidney Health Dis. 2016;3:14. 10.1186/s40697-016-0107-8
9. Goldfrank LR, Flomenbaum NF, Lewin NA, Weisman RS, Howland MA, Hoffman RS. Goldfrank’s toxicologic emergencies. 6th ed. Stamford (CT): Appleton & Lange; 1998. 694–5 p.
10. Fernandez MC, Walter FG, Petersen LR, Walkotte SM. Gabapentin, valproic acid, and ethanol intoxication: Elevated blood levels with mild clinical effects. J Toxicol Clin Toxicol. 1996;34(4):437–9. 10.3109/15563659609013815
11. Verma A, St Clair EW, Radtke RA. A case of sustained massive gabapentin overdose without serious side effects. Therap Drug Monit. 1999;21:615–17. 10.1097/00007691-199912000-00006
12. Fernandez MC, Walter FG, Kloster JC, Do SM, Brady LA, Villarin A, et al. Hemodialysis and hemoperfusion for treatment of valproic acid and gabapentin poisoning. Vet Human Toxicol. 1996;38:438–43.
13. Ibrahim H, Oman Z, Schuelke M, Edwards JC. Treatment of gabapentin toxicity with peritoneal dialysis: Assessment of gabapentin clearance. Am J Kidney Dis. 2017;70(6):878–80. 10.1053/j.ajkd.2017.05.010
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.